Predictive and prognostic significance of PIOS (Patras Immunotherapy Score) model in patients with advanced NSCLC treated with nivolumab or pembrolizumab: Results from a validation cohort.

Foteinos-Ioannis D. Dimtrakopoulos,Giannis Mountzios,Petros Christopoulos,Thomas Papastergiou,Eleftherios Zervas,Sofia Agelaki,Epaminondas Samantas,Ilias Athanasiadis,Sofia Baka,Kostas N. Syrigos,Athina Christopoulou,Evangelos Lianos,Nikolaos Tsoukalas,Eleni Isidora Perdikouri,Georgios Oikonomopoulos,Foteini Kalofonou,Thomas Makatsoris,Angelos Koutras,Vasileios Megalooikonomou,Haralabos P. Kalofonos

Predictive and prognostic significance of PIOS (Patras Immunotherapy Score) model in patients with advanced NSCLC treated with nivolumab or pembrolizumab: Results from a validation cohort.

2021

e21164Background: The treatment of advanced non-small cell lung cancer (aNSCLC) has tremendously changed during the last few years, especially, since immune checkpoint inhibitors (ICIs) were incorp...

Keywords:

non small cell
Nivolumab
Medicine
Internal medicine
Oncology
in patient
Pembrolizumab
validation cohort
Immunotherapy
immune checkpoint inhibitors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations